The German Federal Institute for Drugs and Medical Devices (BfArM) approved our study on "Efficacy and Safety of Psilocybin in Treatment-Resistant Depression" (EPIsoDE).

Our study with psylocin in depression was recommended for funding from the German Federal Ministry of Education and Research.

The 14. Symposium of the task force Therapeutic Drug Monitoring of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) will be held between May 13 and 15, 2020, in Mannheim.

A video of my talk given at the Insight Conference in Berlin on Psychedelic Science on September 6th, 2019.

My lecture on "Hot Topic: Psychopharmaka", held in Mainz on March 15th, 2019, as part of the teaching event "Psychiatrie Update 2019", was videotaped.

A case-control study published in the Lancet Psychiatry further underlines that daily use of high-potency cannabis increases the risk for psychosis.

Two recent publications in the Lancet Planetary Health and JAMA Psychiatry point to the importance of air pollution, especially of nitrogen oxides, for physical and mental health.

In a world, in which robots replace human beings as caregivers, human contact becomes a luxury good.

A brief post on some interviews I gave recently on esketamine for treatment-resistant depression and depression in women who have problems getting pregnant.

Reports on a press conference on digital psychiatry held at the recent DGPPN congress in Berlin (27.11. - 1.12.2018) have been published in various media.

Janssen Pharmaceuticals announced that the company on September 4th, 2018, submitted a New Drug Application to the US FDA for esketamine nasal spray for treatment-resistant depression.

A brief radio feature on "Digital Phenotyping" was broadcasted on August 8, 2018, on Deutschlandfunk.

The Institute for Quality and Efficiency in Health Care (IQWiG) on July 16, 2018, published its opinion on cariprazine as part of its „benefit assessment“. It concludes that there is an "indication" that cariprazine has a "non-quantifiable added benefit" in the group of patients with schizophrenia with predominant negative symptoms.

Lecture on "The Crisis of Psychopharmacology" at the scientific colloquium of the Department of Psychiatry and Psychotherapy of the University of Rostock.

An article on the front page of the New York Times on April 7, 2018, has fueled the debate over antidepressants again.

In the March issue of Nature Biotechnology, Teresa Evans of the University of San Antonio, Texas, and co-authors point out that there is "Evidence for a mental health crisis in graduate education".

My presentation on "long-term treatment with psychotropic drugs" ("Langzeittherapie mit Psychopharmaka") on the web platform "Frag-den-Professor".

A video of my lecture on "Polypharmacy and Pharmacokinetics", which I gave at the "Psychiatrie-Akademie" in Brugg, Switzerland on January 11th, 2018. This talk was given in German.

The American College of Neuropsychopharmacology held its annual meeting between December 3rd and 7th, 2017, in Palm Springs, California. Here is a brief report of some of the meeting highlights.

The staff of my unit at the Department of Psychiatry, Psychotherapy and Psychosomatics at RWTH Aachen University organized a farewell party for me.

Viennese psychiatrist Viktor Frankl on the power of "meaning" man has to find in life and his conception of a rehumanized psychiatry.

The former NIMH director Tom Insel believes that "digital phenotyping" moves psychiatry in a new direction.

The new "Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017" were just published.

My "Mind and Brain Blog" becomes "Mind and Brain Institute", where I will develop the utopia of a better world in the future.

A brief report from the first congress of the International Society for Nutritional Psychiatry Research (ISNPR), which emphasizes the importance of nutrition.